Bank of America
NVCT icon

Bank of America’s Nuvectis Pharma NVCT Stock Holding History

Bank of America’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$218K Sell
11,870
-2,977
-20% -$33.3K ﹤0.01% 5347
2026
Q1 		$115K Buy
14,847
+1,377
+10% +$11.8K ﹤0.01% 5501
2025
Q4 		$102K Buy
13,470
+5,428
+67% +$35.4K ﹤0.01% 5617
2025
Q3 		$48.4K Sell
8,042
-523
-6% -$3.6K ﹤0.01% 6848
2025
Q2 		$64K Buy
8,565
+6,909
+417% +$62.7K ﹤0.01% 6712
2025
Q1 		$16.2K Buy
1,656
+41
+3% +$295 ﹤0.01% 7020
2024
Q4 		$8.74K Buy
1,615
+855
+113% +$5.36K ﹤0.01% 7009
2024
Q3 		$4.78K Sell
760
-4
-0.5% -$26 ﹤0.01% 7021
2024
Q2 		$4.84K Sell
764
-3,011
-80% -$20.5K ﹤0.01% 7011
2024
Q1 		$31K Sell
3,775
-3,730
-50% -$31.7K ﹤0.01% 6651
2023
Q4 		$62.6K Buy
7,505
+1,367
+22% +$12.2K ﹤0.01% 6542
2023
Q3 		$79.1K Buy
6,138
+4,782
+353% +$69.3K ﹤0.01% 6346
2023
Q2 		$21.7K Buy
1,356
+1,192
+727% +$19K ﹤0.01% 6690
2023
Q1 		$2.15K Buy
164
+152
+1,267% +$1.54K ﹤0.01% 7209
2022
Q4 		$90 Buy
+12
New +$86 ﹤0.01% 7688

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Bank of America's NVCT Position: Q2 2026 in Review

Bank of America reduced its Nuvectis Pharma (NVCT) stake by 20% in Q2 2026, selling an estimated $33.3K and leaving 11,870 shares worth $218K. The position accounts for ﹤0.01% of the portfolio, ranked #5347.

Bank of America first reported a position in NVCT in Q4 2022 and has held it in 15 quarters since. 82 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Bank of America held 11,870 shares of Nuvectis Pharma worth $218K as of Q2 2026.
  • Bank of America sold 2,977 Nuvectis Pharma shares in Q2 2026, an estimated $33.3K.
  • Nuvectis Pharma made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #5347 holding.
  • Bank of America first reported a position in Nuvectis Pharma in Q4 2022 and has held it in 15 quarters since.
  • 82 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.